Crohn's disease 1 , 2 and ulcerative colitis, the two main types of chronic inflammatory
bowel disease, are multifactorial conditions of unknown aetiology. A susceptibility locus for …

Background & Aims : Adherent-invasive Escherichia coli (AIEC) pathovar has been identified
in the intestinal mucosa of patients with Crohn’s disease (CD). AIEC reference strain LF82 …

Background The comparative efficacy and safety of infliximab and azathioprine therapy alone
or in combination for Crohn's disease are unknown. Methods In this randomized, double-…

Background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor
α, is an established treatment for Crohn's disease but not ulcerative colitis. Methods Two …

Background & Aims: This study evaluated the efficacy and safety of adalimumab, a fully
human, anti–tumor necrosis factor monoclonal antibody administered subcutaneously, in the …

BACKGROUND & AIMS: In the Active Ulcerative Colitis Trial (ACT)-1 and ACT-2, patients with
ulcerative colitis treated with infliximab were more likely than those given placebo to have …

Objective Vedolizumab is a gut-selective antibody to α 4 β 7 integrin for the treatment of
ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety …

CROHN'S disease (CD) and ulcerative colitis are the major forms of chronic inflammatory
bowel diseases in the western world, and occur in young adults with an estimated prevalence …

The discovery of a series of genetic and serological markers associated with disease
susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an …

Background Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute
effective treatment for ulcerative colitis. Methods We conducted two integrated randomized, …